FIGURE 1. Immunogenicity of heterologous rAd prime-boost vaccine regimens.
From the following article:
Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
Jinyan Liu, Kara L. O'Brien, Diana M. Lynch, Nathaniel L. Simmons, Annalena La Porte, Ambryice M. Riggs, Peter Abbink, Rory T. Coffey, Lauren E. Grandpre, Michael S. Seaman, Gary Landucci, Donald N. Forthal, David C. Montefiori, Angela Carville, Keith G. Mansfield, Menzo J. Havenga, Maria G. Pau, Jaap Goudsmit & Dan H. Barouch
Nature 457, 87-91(1 January 2009)
doi:10.1038/nature07469
Rhesus monkeys were primed at week 0 and boosted at week 24 with rAd26/rAd5, rAd35/rAd5 or rAd5/rAd5 regimens expressing SIV Gag. a, Gag-specific IFN-
ELISPOT assays were performed at weeks 0, 2, 24, 26 and 52 after immune priming. b, CD4+ (white bars) and CD8+ (black bars) T lymphocyte responses were evaluated at week 28 by CD8-depleted and CD4-depleted ELISPOT assays, respectively. SFC, spot-forming cells. c, The breadth of responses was determined by Gag epitope mapping at week 28. d, Gag-specific antibody responses were determined by ELISA at week 28. Mean responses with standard errors are shown (a–d). e, Functionality of Gag-specific CD8+ and CD4+ central memory (CM; CD28+CD95+) and effector memory (EM; CD28-CD95+) T lymphocyte responses were assessed by 8-colour ICS assays. Proportions of IFN-, TNF-
and IL-2 responses are depicted individually and in all possible combinations for each cellular subpopulation. CD4+ EM responses after rAd5/rAd5 immunization were below the detection limit of the assay.
Download file
If the slide opens in your browser, select "File > Save As" to save it.
Download Power Point slide (531K)Slides may be downloaded for educational use, according to the terms described in Nature Publishing Group's licensing policy.
BACK TO ARTICLE